RxDoctor Payments Data

Diana Cooper

Psychiatric/Mental Health · Archdale, NCNPI 1922649516

Payments from drug & device makers

$1,509in general payments, 2019–2025

Across 32 payments — averaging $47.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$502
  • Neurocrine Biosciences, Inc.$341
  • Alkermes, Inc.$224
  • Vanda Pharmaceuticals Inc.$138
  • Supernus Pharmaceuticals, Inc.$110
  • Teva Pharmaceuticals USA, Inc.$101
  • plus $92 from 1 others

What the payments were for

  • Food & beverage$1,509100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,509 in reported general payments places this provider in the 70th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$6,764
Medicare patients
26
Services billed
89

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate34$261,508
Invega SustennaPaliperidone Palmitate31$111,731
VraylarCariprazine Hcl62$91,545
Abilify MaintenaAripiprazole11$31,578
Buspirone Hcl269$7,520
Hydroxyzine Hcl156$4,731
Bupropion XlBupropion Hcl118$3,710
Aripiprazole112$2,745
Quetiapine Fumarate131$2,425
Divalproex Sodium ErDivalproex Sodium64$2,390
Mirtazapine162$2,010
Trazodone Hcl265$1,983
Hydroxyzine Pamoate65$1,623
Gabapentin117$1,575
Duloxetine Hcl123$1,527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$341$261,50834 claims
AbbVieVraylar$502$91,54562 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$92$31,57811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Archdale

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →